Cipher Pharmaceuticals to Present at 2015 JMP Securities Life Sciences Conference

MISSISSAUGA, ON, June 19, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O’Brien, President and Chief Executive Officer, will present at the 2015 JMP Securities Life Sciences Conference in New York on Tuesday, June 23, 2015. The presentation will take place at 9:30 AM ET and will be followed by a Q&A session. A live audio webcast of the presentation will be available by accessing the Investor Relations section of the Company’s website at www.cipherpharma.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for six months. About Cipher […]

Cipher Pharmaceuticals to Present at BIO International Convention

MISSISSAUGA, ON, June 4, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O’Brien, President and Chief Executive Officer, will present at the BIO International Convention in Philadelphia on Tuesday, June 16, 2015. The presentation will take place at 11:30 AM ET in Theater 3 and will be followed by a Q&A session. About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products that is on pace to achieve its goal of becoming the most customer-centric dermatology company in North America. Cipher acquires best-in-class products […]

Cipher Pharmaceuticals Strengthens Leadership Team with Key Executive Appointments and Announces Launch of Vaniqa® in Canada

– Company Adds Regulatory and Alliance Management Expertise to Support Expanded Product Portfolio – MISSISSAUGA, ON, June 2, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (“Cipher” or “the Company”) today announced the appointments of Louise Blythe as Vice President, Regulatory Affairs and Brian Rosenberger as Vice President, Alliance and Strategic Portfolio Management. In addition, the Company announced the promotions of Joan Chypyha to President and General Manager, Canada and Joe Pecora to President and General Manager, USA. Ms. Blythe brings to Cipher 16 years’ of experience in Regulatory Affairs in the pharmaceutical industry. Most recently, she served as Director […]

Cipher Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference

MISSISSAUGA, ON, May 28, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced that Shawn Patrick O’Brien, President and Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in New York on Tuesday, June 2, 2015. Cipher is scheduled to present at 2:00 PM ET, followed immediately by a Q&A breakout session. Cipher’s presentation will be webcast live and may be accessed from the Investor Relations section of the Company’s website at www.cipherpharma.com. About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (NASDAQ:CPHR; TSX:CPH) is a rapidly growing specialty pharmaceutical dermatology company with a diversified portfolio of commercial-stage products that […]

Cipher Pharmaceuticals Inc. Reports Voting Results from Annual and Special Meeting of Shareholders

MISSISSAUGA, ON, May 14, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (“Cipher” or “the Company”), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special Meeting of Shareholders held on May 13, 2015 in Toronto, Ontario. A total of 16,646,008 million common shares representing 64.29% of the Company’s issued and outstanding common shares were voted in connection with the meeting. Shareholders voted in favour of all items of business put forth. The votes for the election of directors are as follows:   Motions % of Shares Voted For % of Shares Voted Withhold Elect […]

Cipher Reports Financial and Operational Results for Q1 2015

– Company Achieves Significant Progress Across All Three Components of Growth Strategy – MISSISSAUGA, ON, May 13, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (“Cipher” or “the Company”) today announced its financial and operational results for the three months ended March 31, 2015.  Highlights for the quarter Total revenue increased 17% to $9.2 million from $7.9 million in Q1 2014; Strong revenue generated from all three commercialized products: Absorica revenues increased 5% to $6.3 million from $6.0 million in Q1 2014; Epuris revenues were up 139% year-over-year to $0.8 million for Q1 2015; Lipofen revenue was $1.6 million in […]

Cipher Pharmaceuticals Acquires Canadian Commercialization Rights to Vaniqa® and Actikerall®

MISSISSAUGA, ON, May 6, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (“Cipher” or “the Company”) today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa® and Actikerall® from Almirall S. A., a Spanish pharmaceutical company.  Both products have been approved by Health Canada. VANIQA is a prescription cream clinically proven to reduce the growth of unwanted facial hair in women. VANIQA cream is an enzyme inhibitor and works by blocking an enzyme necessary for hair to grow. The product was approved by Health Canada in May, 2001. Actikerall is indicated for the topical treatment of […]

Notice of Cipher Pharmaceuticals Inc. Q1 2015 Conference Call and 2014 Annual and Special Meeting of Shareholders

MISSISSAUGA, ON, April 29, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q1 2015 financial results and hold its Annual and Special Meeting of Shareholders on Wednesday, May 13, 2015. Q1 2015 CONFERENCE CALL WHEN: May 13, 2015 at 08:30 AM ET CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com/  or  http://bit.ly/1OeDdfu. An archived replay of the webcast will be available for 365 days. ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS WHEN: May 13, 2015 at 11:00 AM ET WHERE: […]

Cipher Pharmaceuticals announces outcome of Markman hearing in patent infringement suit for Absorica®

MISSISSAUGA, ON, April 24, 2015 /CNW/ – Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (“Cipher” or “the Company”) today announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a “Markman hearing”) for the patent infringement suit by Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc., (“Ranbaxy”), a Sun Pharma Company, Galephar Pharmaceutical Research Inc., and Cipher against Watson Laboratories, Inc. (“Watson”, now Actavis plc, NYSE:ACT) related to Watson’s Abbreviated New Drug Application (ANDA) for a generic version of Absorica® (isotretinoin capsules). The purpose of a Markman hearing is to determine the precise meaning of words from patent […]